ENGLEWOOD, Colo., Sept. 19, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26th-28th, 2023.
Zynex's presentation will be held in person and webcast live on September 26th at 1:35 PM ET at the InterContinental Barclay Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Thomas Sandgaard, Founder and CEO, and Dan Moorhead, CFO, will be available for one-on-one meetings on September 26th and 27th.
To receive additional information, register to attend, or schedule a one-on-one meeting, email the Cantor team at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.16 |
Daily Volume: | 341,666 |
Market Cap: | US$68.800M |
December 12, 2024 December 05, 2024 October 24, 2024 September 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load